Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy
Francesco Saverio Mennini, Paolo Bonanni, F. Bianic, et al.
Cost Effectiveness and Resource Allocation (2017) Vol. 15, Iss. 1
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

<p>Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus</p>
Zheng Quan Toh, Jennie Kosasih, Fiona M. Russell, et al.
Infection and Drug Resistance (2019) Vol. Volume 12, pp. 1951-1967
Open Access | Times Cited: 50
Prevalence and genotype distribution of genital human papillomavirus infection in female sex workers in the world: a systematic review and meta-analysis
Mohammad Farahmand, Mohsen Moghoofei, Abolfazl Dorost, et al.
BMC Public Health (2020) Vol. 20, Iss. 1
Open Access | Times Cited: 44
Cost-effectiveness analysis of switching from a bivalent to a nonavalent HPV vaccination programme in China: a modelling study
Meng Gao, Shangying Hu, Xuelian Zhao, et al.
The Lancet Regional Health - Western Pacific (2025) Vol. 56, pp. 101499-101499
Open Access
A cost-effectiveness analysis of adult human papillomavirus vaccination strategies in Italy
Alhaji Cherif, Cody Palmer, Francesca Senese, et al.
Human Vaccines & Immunotherapeutics (2025) Vol. 21, Iss. 1
Open Access
Validating the predicted impact of HPV vaccination on HPV prevalence, cervical lesions, and cervical cancer: A systematic review of population level data and modelling studies
Daniel D de Bondt, Emi Naslazi, Erik E.L. Jansen, et al.
Gynecologic Oncology (2025) Vol. 195, pp. 134-143
Open Access
Current issues facing the introduction of human papillomavirus vaccine in China and future prospects
Li Ping Wong, Liyuan Han, Hui Li, et al.
Human Vaccines & Immunotherapeutics (2019) Vol. 15, Iss. 7-8, pp. 1533-1540
Open Access | Times Cited: 34
Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: Evidence from a systematic review
Rashidul Alam Mahumud, Khorshed Alam, Syed Afroz Keramat, et al.
PLoS ONE (2020) Vol. 15, Iss. 6, pp. e0233499-e0233499
Open Access | Times Cited: 25
Cost-effectiveness of extending the HPV vaccination to boys: a systematic review
Renata Linertová, Carmen Guirado-Fuentes, Javier Mar, et al.
Journal of Epidemiology & Community Health (2021) Vol. 75, Iss. 9, pp. 910-916
Closed Access | Times Cited: 20
Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain
Jesús de la Fuente, Juan José Hernández Aguado, María San Martín, et al.
Human Vaccines & Immunotherapeutics (2019) Vol. 15, Iss. 7-8, pp. 1949-1961
Open Access | Times Cited: 24
Public health impact and cost-effectiveness of a nine-valent gender-neutral HPV vaccination program in France
Laureen Majed, Xavier Bresse, Nadia El Mouaddin, et al.
Vaccine (2020) Vol. 39, Iss. 2, pp. 438-446
Closed Access | Times Cited: 22
A two-sex model of human papillomavirus infection: Vaccination strategies and a case study
Shasha Gao, Maia Martcheva, Hongyu Miao, et al.
Journal of Theoretical Biology (2022) Vol. 536, pp. 111006-111006
Open Access | Times Cited: 12
History of Human Papilloma Virus Vaccination with a Focus on Italy
Giovanni Gabutti, Matilde Ogliastro
Women (2024) Vol. 4, Iss. 1, pp. 42-52
Open Access | Times Cited: 2
Human Papilloma Virus Vaccination and Cervical Screening in the Italian Regions: An Overview of the Current State of the Art
Angela Bechini, Claudia Cosma, Giulia Di Pisa, et al.
Vaccines (2024) Vol. 12, Iss. 5, pp. 504-504
Open Access | Times Cited: 2
Cost-effectiveness and epidemiological impact of gender-neutral HPV vaccination in Spain
Renata Linertová, Carmen Guirado-Fuentes, Javier Mar, et al.
Human Vaccines & Immunotherapeutics (2022) Vol. 18, Iss. 6
Open Access | Times Cited: 10
Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysis
Yawen Jiang, Weiyi Ni, Jing Wu
BMJ Open (2019) Vol. 9, Iss. 11, pp. e031186-e031186
Open Access | Times Cited: 16
Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong
Tak Hong Cheung, Sally Shuk Yee Cheng, Danny Hsu, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 2
Open Access | Times Cited: 5
Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh
Rashidul Alam Mahumud, Jeff Gow, Khorshed Alam, et al.
Vaccine (2019) Vol. 38, Iss. 2, pp. 165-172
Closed Access | Times Cited: 14
Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland
André B. Kind, Andrew Pavelyev, Smita Kothari, et al.
BMC Public Health (2020) Vol. 20, Iss. 1
Open Access | Times Cited: 13
Cost-effectiveness analysis of quadrivalent and nonavalent human papillomavirus vaccines in Ethiopia
Abrham Wondimu, Maarten J. Postma, Marinus van Hulst
Vaccine (2022) Vol. 40, Iss. 14, pp. 2161-2167
Open Access | Times Cited: 8
Uptake of human papilloma virus vaccine and intention to vaccinate among women in Saudi Arabia
Alaa Sami Barhamain, Osama Mohammed Alwafi
Medical Science (2022) Vol. 26, Iss. 123, pp. 1-1
Open Access | Times Cited: 8
The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia
Rashidul Alam Mahumud, Khorshed Alam, Jeff Dunn, et al.
PLoS ONE (2019) Vol. 14, Iss. 10, pp. e0223658-e0223658
Open Access | Times Cited: 12
Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore
Lee Cheng Phua, Cheuk‐Wai Choi, Joseph T. Wu, et al.
Vaccine (2021) Vol. 39, Iss. 16, pp. 2255-2263
Closed Access | Times Cited: 11
Vaccinating women previously treated for human papillomavirus-related cervical precancerous lesions is highly cost-effective in China
Maosheng Zou, Hanting Liu, Huan Liu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 4
Present challenges in cervical cancer prevention: Answers from cost-effectiveness analyses
Mireia Díaz, Silvia de Sanjosé, F. Xavier Bosch, et al.
Reports of Practical Oncology & Radiotherapy (2018) Vol. 23, Iss. 6, pp. 484-494
Open Access | Times Cited: 11
Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium
Steven Simoens, André Bento‐Abreu, Barbara Merckx, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top